Shree Ganesh Remedies LtdQ1 FY25Pharmaceuticals & Biotechnology

Shree Ganesh Remedies Ltd

Q1 FY25 Earnings Call Analysis

Management growth scorecard

Revenue

Category 3

Margin

Category 4

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Revenue guidance

Category 3

→Current revenue is approximately ₹109 crore, with 15-20% from CRAMS projects.
→Revenue is expected to double over the next 3-4 years, driven largely by CRAMS and new projects.
→CRAMS revenue will increase steadily, potentially doubling or tripling in the future.
→No single project contributes ₹100 crore currently; peak revenues for key projects are around ₹30-35 crore annually.
→Larger scale projects with volumes above 200-500 metric tons are in the pipeline, supporting growth.
→FY26 is expected to be a consolidation year with moderate top-line growth and margin normalization.
→CRAMS commercialization and approvals anticipated to support commercial supplies starting from mid-FY26 onwards.
→Base business (pharma intermediates and specialty chemicals) projected to grow at mid-teens CAGR over the medium term.
→Investments in R&D, capacity-building, and new chemistries are aligned with anticipated project demands to support future scale-up.

Category 4

→FY26 is expected to be a year of consolidation with moderate top-line growth and margin normalization to 24-26% range due to pricing pressures and ramp-up costs.
→Revenue growth is projected at a moderate pace rather than drastic increase in FY26.
→Over the next 3-4 years, revenue is expected to double driven by growth in CRAMS projects and new product commercialization with a targeted CAGR of 20-25%.
→New large-scale CRAMS projects with high-volume (>200 tons) and customer-specific custom synthesis are key growth drivers.
→Infrastructure and R&D investments are anticipated to enable accelerated and profitable growth beyond FY26.
→Profitability will improve as new manufacturing capacities become better utilized and higher margin CRAMS volumes ramp up.
→EPS growth will follow revenue and margin expansion as commercial supplies from CRAMS projects commence, especially in FY27-29 timeframe.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Shree Ganesh Remedies Ltd and 1,400+ other companies.

→There is no mention of any current or planned fundraising through debt or equity in the transcript.
→The company is funding its strategic investments, including infrastructure and capacity expansions, through internal accruals.
→The focus is on operational consolidation and capacity building in FY26 with approximate CapEx of around ₹15 crore.
→No indications were given about raising external capital; emphasis is on financial prudence and using internal resources for growth initiatives.

→The company is actively working on multiple custom synthesis (crams) projects, with 6 projects typically closed in the lab annually.
→Current crams revenue is approximately 15-20% of total revenue, expected to grow steadily over the next few years.
→The order book includes projects with peak volumes above 200 metric tons; e.g., agrochemical and Japanese projects targeting 250-500+ metric tons.
→New innovative multi-step complex products are in development with a few projects expected to generate annual revenues of 30-35+ crore at peak.
→No single project currently expected to add 100 crore in FY27; growth anticipated through a portfolio of small-to-medium projects.
→FY26 is seen as a consolidation year with capacity building and approvals underway, preparing for commercial supply ramp-up in FY27-28.
→The Dahej site is being developed with utilities and infrastructure to support large-scale projects as firm orders materialize.

Yes

→The company has invested significantly in R&D, infrastructure, and capacity over the last two years, focusing on projects they anticipate will commercialize in the near future.
→CapEx remains aggressive with ongoing construction of manufacturing Block 9 near Plant 8, and a new pilot plant near Plant 4 to support advanced chemistries including flow chemistry.
→Planned CapEx for FY26 is approximately ₹15 crore, mainly for manufacturing blocks and pilot plant.
→Development of common infrastructure and utilities at the Dahej site is underway to support large-scale CRAMS projects.
→Expansion at the Ankleshwar site is preferred for manufacturing infrastructure with ample space after acquiring neighboring land.
→Strategic investment supports new technologies and equipment necessary for complex specialty chemical projects, including flow and other advanced chemistries.
→A 2.5 MW solar power park was recently commissioned, contributing up to 70% of electricity from renewable sources, underlining commitment to sustainable manufacturing.

How does Shree Ganesh Remedies Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Shree Ganesh Remedies Ltd

Rev 3Mar 4

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Shree Ganesh Remedies Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.